An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Inclusion Criteria:

• Have an established histological diagnosis of selected solid tumor and must havereceived and progressed on established standard therapies or have been intolerant tosuch therapy or have been considered by the Investigator as ineligible for approvedstandard therapy

• Have a life expectancy≥12 weeks at the time of the screening

• Women of childbearing potential must agree to use highly effective methods ofcontraception for the course of the trial through 120 days after the last dose oftrial medication

• Males who are sexually active with women of childbearing potential must agree to usecondoms and refrain from donating sperm for the course of the trial through 120 daysafter the last dose of trial medication

NOTE- Additional criteria apply, please contact the investigator for more information

Exclusion Criteria:

• Has a history of systemic treatment therapy for cancer (including chemotherapy,immunotherapy, radiotherapy, or other investigational drug) or surgery within 4weeks prior to baseline

• Is currently receiving or has received hematopoietic colony-stimulating growthfactors within 2 weeks before screening or transfusion support 4 weeks prior toscreening

• Has a diagnosis of immunodeficiency

• Has active known autoimmune disease.

• Has a history of or known active brain metastases and/or carcinomatous meningitisand/or leptomeningeal metastasis

• Has active or uncontrolled serious infections requiring systemic therapy within 14days prior to baseline

• Has a history of clinically significant cardiovascular or cerebrovascular disease inprevious 6 months prior to screening

• Has evidence of clinically significant interstitial lung disease or active,noninfectious pneumonitis

• Has a seizure disorder requiring therapy (such as steroids or antiepileptics)

NOTE- Additional criteria apply, please contact the investigator for more information